The Lancet Commission on diabetes: using data to transform diabetes care and patient lives

Chan, Juliana C.N.; Lim, Lee‐Ling; Wareham, Nicholas J.; Shaw, Jonathan E.; Orchard, Trevor J.; Zhang, Ping; Lau, Eric S. H.; Eliasson, Björn; Kong, Alice P.S.; Ezzati, Majid; Aguilar-Salinas, Carlos A.; McGill, Margaret; Levitt, Naomi; Ning, Guang; So, Wing‐Yee; Adams, Jean; Bracco, Paula A.; Forouhi, Nita G.; Gregory, Gabriel A; Guo, Jingchuan; Hua, Xinyang; Klatman, Emma L; Magliano, Dianna J.; Ng, Boon-Peng; Ogilvie, David; Panter, Jenna; Pavkov, Meda E.; Shao, Hui; Unwin, Nigel; White, Martin; Wou, Constance; Ronald, C.; Schmidt, María Inês; Ramachandran, Ambady; Seino, Yutaka; Bennett, Peter H.; Oldenburg, Brian; Gagliardino, Juan José; Luk, Andrea; Clarke, Philip; Ogle, Graham D; Davies, Melanie J.; Holman, Rury R.; Gregg, Edward W.

doi:10.1016/s0140-6736(20)32374-6

Cited by 461 publications

(474 citation statements)

References 458 publications

Supporting

Mentioning

449

Contrasting

Unclassified

Order By: Relevance

“…This figure is available as part of a downloadable slideset At a global level, the United Nations' sustainable development goals (SDGs) [54] include targets on NCDs, access to medicines and universal health coverage (UHC), which should guide the global response to diabetes [46]. For type 1 diabetes, many countries do not necessarily provide full coverage for insulin and diabetes supplies within the context of UHC [55]; should these be provided in a comprehensive way, this could have an impact on mortality [56]. To date, the…”

Section: Resultsmentioning

confidence: 99%

A global perspective on the issue of access to insulin

et al. 2021

View full text Add to dashboard Cite

The discovery of insulin in 1921 changed the prognosis for people with type 1 diabetes. A century later, availability and affordability of insulin remain a challenge in many parts of the globe. Using the WHO’s framework on understanding the life cycle of medicines, this review details the global and national challenges that affect patients’ abilities to access and afford insulin. Current research and development in diabetes has seen some innovations, but none of these have truly been game-changing. Currently, three multinational companies control over 95% of global insulin supply. The inclusion of insulin on the WHO’s Prequalification Programme is an opportunity to facilitate entry of new companies into the market. Many governments lack policies on the selection, procurement, supply, pricing and reimbursement of insulin. Moreover, mark-ups in the supply chain also affect the final price to the consumer. Whilst expenses related to diabetes are mostly covered by insurance in high-income countries, many patients from low- and middle-income countries have to pay out of their own pockets. The organisation of diabetes management within the healthcare system also affects patient access to insulin. The challenges affecting access to insulin are complex and require a wide range of solutions. Given that 2021 marks the centenary of the discovery of insulin, there is need for global advocacy to ensure that the benefits of insulin and innovations in diabetes care reach all individuals living with diabetes. Graphical abstract

show abstract

Section: Resultsmentioning

confidence: 99%

A global perspective on the issue of access to insulin

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A panel convened by The Lancet has published a report calling for major initiatives to improve diabetes prevention and care, for the 463 million people living with diabetes around the world 6 . Spurred on by the impact of the COVID‐19 pandemic on people living with diabetes, the commission has called for the use of evidence‐based interventions to prevent thousands of deaths globally every day.…”

Section: The Lancet Commission On Diabetesmentioning

confidence: 99%

Update on technologies, medicines and treatments

O’Neill

2021

Diabet Med

View full text Add to dashboard Cite

“…WHO and diabetes organisations have encouraged the establishment of registries; however, progress remains weak in LMICs, where 80% of diabetes-related deaths occur. 4 National diabetes registries are clustered in high-income and upper-middle-income countries, and these often collect insufficient patient data: many focus exclusively on type 1 diabetes, whereas type 2 diabetes accounts for 95% of global cases. 5 Some LMICs have hospital and localised registries, but the national registries that facilitate the wider benefits of understanding the prevalence and characteristics of diabetes in a country and intervention-targeting are scarce.…”

mentioning

confidence: 99%